Clinical trial Recruiting at 2 sites Observational Ages 50 to 70

Non-invasive urine and stool tests for early colorectal cancer diagnosis

Official title: Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile

Run by Institut Investigacio Sanitaria Pere Virgili · NCT06452745 · Data updated 2026-11-12

This study is testing if special urine and stool tests can help find colorectal cancer early in patients who have already had a positive blood test.

More Colorectal Cancer trials

Quick facts

Study typeObservational
Ages50 Years to 70 Years
SexAll
Enrollment2000 (estimated)
SponsorInstitut Investigacio Sanitaria Pere Virgili
Academic / other
Drugs / interventionschemotherapy, radiation
Locations2 sites (Reus, Tarragona and 1 other locations)
StatusRecruiting
StartedJuly 20, 2019
Main results expectedJune 30, 2030
Study endsJune 30, 2040
Registry record updatedOctober 2, 2024
Trial IDNCT06452745 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with a positive FOBT result who are being referred for a colonoscopy.

Probably not a fit

Patients with other primary cancers diagnosed in the last five years or severe kidney or liver diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to identify specific metabolites in urine and stool samples that can differentiate between patients with colorectal cancer or polyps and healthy individuals. By utilizing metabolomics techniques, the study seeks to develop a cost-effective and non-invasive screening method for early diagnosis of colorectal cancer. The research focuses on patients who have tested positive in a fecal occult blood test (FOBT) and are referred for colonoscopy. The goal is to improve early detection rates and ultimately reduce mortality associated with colorectal cancer.

Why it matters

Potential benefit: If successful, this approach could lead to earlier and more accurate diagnosis of colorectal cancer, improving patient outcomes.

How similar studies have gone: While there have been studies exploring metabolomics in cancer detection, this specific approach focusing on non-invasive urine and stool analysis is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy.

Exclusion Criteria:

* Patients diagnosed with another primary neoplasm in the last 5 years, with the exception of carcinoma in situ of the cervix or non-melanoma skin cancer.
* Patients with severe kidney disease stage IV (creatinine clearance \< 30 ml/min).
* Patients with severe active liver disease (hepatitis, cirrhosis).
* Refusal to sign informed consent.

Where it's running

  • Hospital Universitari Sant Joan de Reus
    Reus, Tarragona, Spain
    Recruiting
  • Hospital Universitari Joan XXIII
    Tarragona, Tarragona, Spain
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.